BR112022018996A2 - 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52". - Google Patents

3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".

Info

Publication number
BR112022018996A2
BR112022018996A2 BR112022018996A BR112022018996A BR112022018996A2 BR 112022018996 A2 BR112022018996 A2 BR 112022018996A2 BR 112022018996 A BR112022018996 A BR 112022018996A BR 112022018996 A BR112022018996 A BR 112022018996A BR 112022018996 A2 BR112022018996 A2 BR 112022018996A2
Authority
BR
Brazil
Prior art keywords
pyrazines
substituted
gpr52
phenoxyazetidin
showing
Prior art date
Application number
BR112022018996A
Other languages
English (en)
Portuguese (pt)
Inventor
Gerlach Kai
Bertani Barbara
Ferrara Marco
FOSSATI Giacomo
Hobson Scott
Friederike Lessel Uta
Runge Frank
Semple Graeme
Mueller-Vieira Ursula
Wippich Julian
Xiong Yifeng
Original Assignee
Boehringer Ingelheim Int
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Arena Pharm Inc filed Critical Boehringer Ingelheim Int
Publication of BR112022018996A2 publication Critical patent/BR112022018996A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022018996A 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52". BR112022018996A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
BR112022018996A2 true BR112022018996A2 (pt) 2022-11-01

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018996A BR112022018996A2 (pt) 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".

Country Status (20)

Country Link
US (1) US11780827B2 (https=)
EP (1) EP4126850B1 (https=)
JP (1) JP7617134B2 (https=)
KR (1) KR20220161454A (https=)
CN (1) CN115697997B (https=)
AR (1) AR121675A1 (https=)
AU (1) AU2021250303A1 (https=)
BR (1) BR112022018996A2 (https=)
CA (1) CA3176265A1 (https=)
CO (1) CO2022014886A2 (https=)
CR (1) CR20220554A (https=)
DO (1) DOP2022000203A (https=)
EC (1) ECSP22080683A (https=)
IL (1) IL296823A (https=)
JO (1) JOP20220235A1 (https=)
MX (1) MX2022012067A (https=)
PE (1) PE20221918A1 (https=)
PH (1) PH12022552553A1 (https=)
TW (1) TW202204343A (https=)
WO (1) WO2021198149A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2055500A (en) * 1998-12-23 2000-07-31 Eli Lilly And Company Aromatic amides
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
WO2011078360A1 (ja) * 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) * 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) * 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
KR20180004193A (ko) * 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
CA3176265A1 (en) 2021-10-07
EP4126850B1 (en) 2024-04-17
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
IL296823A (en) 2022-11-01
US20220356172A1 (en) 2022-11-10
JP7617134B2 (ja) 2025-01-17
CR20220554A (es) 2023-01-09
KR20220161454A (ko) 2022-12-06
WO2021198149A1 (en) 2021-10-07
JOP20220235A1 (ar) 2022-09-28
US11780827B2 (en) 2023-10-10
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
CO2022014886A2 (es) 2022-10-31
ECSP22080683A (es) 2022-11-30
AR121675A1 (es) 2022-06-29
CN115697997B (zh) 2024-07-30
TW202204343A (zh) 2022-02-01
PE20221918A1 (es) 2022-12-29
JP2023522307A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112018000041A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
BR112022018996A2 (pt) 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BR112014016648A2 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112017005299A2 (pt) inibidores de lrrk2 cinase macrocíclicos
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BR112021011325A2 (pt) Derivados de rapamicina
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]